


WHAT IS CLAIMED IS:

1. A racemate, diastereoisomer or optical isomer of a compound of formula (I):



wherein **B** is H, a C₆ or C₁₀ aryl, C₇₋₁₆ aralkyl; Het or (lower alkyl)-Het, all of which optionally substituted with C₁₋₆ alkyl; C₁₋₆ alkoxy; C₁₋₆ alkanoyl; hydroxy; hydroxyalkyl; halo; haloalkyl; nitro; cyano; cyanoalkyl; amino optionally substituted with C₁₋₆ alkyl; amido; or (lower alkyl)amide; or **B** is an acyl derivative of formula **R**₄-C(O)-; a carboxyl derivative formula **R**₄-O-C(O)-; an amide derivative of formula **R**₄-N(**R**₅)-C(O)-; a thioamide derivative of formula **R**₄-N(**R**₅)-C(S)-; or a sulfonyl derivative of formula **R**₄-SO₂ wherein

- R**₄ is (i) C₁₋₁₀ alkyl optionally substituted with carboxyl, C₁₋₆ alkanoyl, hydroxy, C₁₋₆ alkoxy, amino optionally mono- or di-substituted with C₁₋₆ alkyl, amido, or (lower alkyl) amide;
- (ii) C₃₋₇ cycloalkyl, C₃₋₇ cycloalkoxy, or C₄₋₁₀ alkylcycloalkyl, all optionally substituted with hydroxy, carboxyl, (C₁₋₆ alkoxy)carbonyl, amino optionally mono- or di-substituted with C₁₋₆ alkyl, amido, or (lower alkyl) amide;
- (iii) amino optionally mono- or di-substituted with C₁₋₆ alkyl; amido; or (lower alkyl)amide;
- (iv) C₆ or C₁₀ aryl or C₇₋₁₆ aralkyl, all optionally substituted with C₁₋₆ alkyl, hydroxy, amido, (lower alkyl)amide, or amino optionally mono- or di-substituted with C₁₋₆ alkyl; or
- (v) Het or (lower alkyl)-Het, both optionally substituted with C₁₋₆ alkyl, hydroxy, amido, (lower alkyl) amide, or amino optionally mono- or di-substituted with C₁₋₆ alkyl;

R₅ is H or C₁₋₆ alkyl;

with the proviso that when **B** is a carboxyl derivative, an amide derivative or a thioamide derivative, **R**₄ is not a cycloalkoxy;

Y is H or C₁₋₆ alkyl;

R³ is C₁₋₈ alkyl, C₃₋₇ cycloalkyl, or C₄₋₁₀ alkylcycloalkyl, all optionally substituted with hydroxy, C₁₋₆ alkoxy, C₁₋₆ thioalkyl, amido, (lower alkyl)amido, C₆ or C₁₀ aryl, or C₇₋₁₆ aralkyl;

R² is CH₂-**R**₂₀, NH-**R**₂₀, O-**R**₂₀ or S-**R**₂₀, wherein **R**₂₀ is a saturated or unsaturated C₃₋₇ cycloalkyl or C₄₋₁₀ (alkylcycloalkyl), all of which being optionally mono-, di- or tri-substituted with **R**₂₁,

or **R**₂₀ is a C₆ or C₁₀ aryl or C₇₋₁₄ aralkyl, all optionally mono-, di- or tri-substituted with **R**₂₁,

or **R**₂₀ is Het or (lower alkyl)-Het, both optionally mono-, di- or tri-substituted with **R**₂₁,

wherein each **R**₂₁ is independently C₁₋₆ alkyl; C₁₋₆ alkoxy; lower thioalkyl; sulfonyl; NO₂; OH; SH; halo; haloalkyl; amino optionally mono- or di-substituted with C₁₋₆ alkyl, C₆ or C₁₀ aryl, C₇₋₁₄ aralkyl, Het or (lower alkyl)-Het; amido optionally mono-substituted with C₁₋₆ alkyl, C₆ or C₁₀ aryl, C₇₋₁₄ aralkyl, Het or (lower alkyl)-Het; carboxyl; carboxy(lower alkyl); C₆ or C₁₀ aryl, C₇₋₁₄ aralkyl or Het, said aryl, aralkyl or Het being optionally substituted with **R**₂₂;

wherein **R**₂₂ is C₁₋₆ alkyl; C₃₋₇ cycloalkyl; C₁₋₆ alkoxy; amino optionally mono- or di-substituted with C₁₋₆ alkyl; sulfonyl; (lower alkyl)sulfonyl; NO₂; OH; SH; halo; haloalkyl; carboxyl; amide; (lower alkyl)amide; or Het optionally substituted with C₁₋₆ alkyl;

R¹ is H; C₁₋₆ alkyl, C₃₋₇ cycloalkyl, C₂₋₆ alkenyl, or C₂₋₆ alkynyl, all optionally substituted with halogen;

or a pharmaceutically acceptable salt or ester thereof;

wherein "Het" is defined as a five-, six-, or seven-membered saturated or unsaturated, aromatic or non-aromatic, heterocycle containing from one to four heteroatoms selected from nitrogen, oxygen and sulfur, wherein said heterocycle is optionally fused to a benzene ring.

2. A compound of formula I according to claim 1, wherein **B** is a C₆ or C₁₀ aryl or C₇₋₁₆ aralkyl, all optionally substituted with C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkanoyl, hydroxy, hydroxyalkyl, halo, haloalkyl, nitro, cyano, cyanoalkyl, amido, (lower alkyl)amido, or amino optionally substituted with C₁₋₆ alkyl; or **B** is Het or (lower alkyl)-Het, all optionally substituted with C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkanoyl, hydroxy, hydroxyalkyl, halo, haloalkyl, nitro, cyano, cyanoalkyl, amido, (lower alkyl)amido, or amino optionally substituted with C₁₋₆ alkyl.
3. A compound of formula I according to claim 1, wherein **B** is **R₄-SO₂** wherein **R₄** is C₁₋₆ alkyl; amido; (lower alkyl)amide; C₆ or C₁₀ aryl, C₇₋₁₄ aralkyl or Het, all optionally substituted with C₁₋₆ alkyl.
4. A compound of formula I according to claim 1, wherein **B** is an acyl derivative of formula **R₄-C(O)-** wherein **R₄** is
 - (i) C₁₋₁₀ alkyl optionally substituted with carboxyl, hydroxy or C₁₋₆ alkoxy, amido, (lower alkyl)amide, or amino optionally mono- or di-substituted with C₁₋₆ alkyl;
 - (ii) C₃₋₇ cycloalkyl or C₄₋₁₀ alkylcycloalkyl, both optionally substituted with hydroxy, carboxyl, (C₁₋₆ alkoxy)carbonyl, amido, (lower alkyl)amide, or amino optionally mono- or di-substituted with C₁₋₆ alkyl;
 - (iv) C₆ or C₁₀ aryl or C₇₋₁₆ aralkyl, all optionally substituted with C₁₋₆ alkyl, hydroxy, amido, (lower alkyl)amide, or amino optionally substituted with C₁₋₆ alkyl;
 - (v) Het or (lower alkyl)-Het, both optionally substituted with C₁₋₆ alkyl, hydroxy, amino optionally substituted with C₁₋₆ alkyl, amido, (lower alkyl)amide, or amino optionally substituted with C₁₋₆ alkyl.
5. A compound of formula I according to claim 1, wherein **B** is a carboxyl derivative of formula **R₄-O-C(O)-**, wherein **R₄** is
 - (i) C₁₋₁₀ alkyl optionally substituted with carboxyl, C₁₋₆ alkanoyl, hydroxy, C₁₋₆ alkoxy, amino optionally mono- or di-substituted with C₁₋₆ alkyl, amido or (lower alkyl)amide;
 - (ii) C₃₋₇ cycloalkyl, C₄₋₁₀ alkylcycloalkyl, all optionally substituted with carboxyl, (C₁₋₆ alkoxy)carbonyl, amino optionally mono- or di-substituted

with C₁₋₆ alkyl, amido or (lower alkyl)amide;

(iv) C₆ or C₁₀ aryl or C₇₋₁₆ aralkyl optionally substituted with C₁₋₆ alkyl, hydroxy, amido, (lower alkyl)amido, or amino optionally mono- or di-substituted with C₁₋₆ alkyl; or

(v) Het or (lower alkyl)-Het, both optionally substituted with C₁₋₆ alkyl, hydroxy, amino optionally mono- or di-substituted with C₁₋₆ alkyl, amido or (lower alkyl)amido.

6. A compound of formula I according to claim 1, wherein **B** is an amide derivative of formula **R₄-N(R₅)-C(O)-** wherein **R₄** is —

(i) C₁₋₁₀ alkyl optionally substituted with carboxyl, C₁₋₆ alkanoyl, hydroxy, C₁₋₆ alkoxy, amido, (lower alkyl)amido, or amino optionally mono- or di-substituted with C₁₋₆ alkyl;

(ii) C₃₋₇ cycloalkyl or C₄₋₁₀ alkylcycloalkyl, all optionally substituted with carboxyl, (C₁₋₆ alkoxy)carbonyl, amido, (lower alkyl)amido, or amino optionally mono- or di-substituted with C₁₋₆ alkyl;

(iii) amino optionally mono- or di-substituted with C₁₋₃ alkyl;

(iv) C₆ or C₁₀ aryl or C₇₋₁₆ aralkyl, all optionally substituted with C₁₋₆ alkyl, hydroxy, amido, (lower alkyl)amide, or amino optionally substituted with C₁₋₆ alkyl; or

(v) Het or (lower alkyl)-Het, both optionally substituted with C₁₋₆ alkyl, hydroxy, amino optionally substituted with C₁₋₆ alkyl, amido or (lower alkyl)amide; and

R₅ is H or methyl.

7. A compound of formula I according to claim 1, wherein **B** is a thioamide derivative of formula **R₄-NH-C(S)-**; wherein **R₄** is

(i) C₁₋₁₀ alkyl optionally substituted with carboxyl, C₁₋₆ alkanoyl or C₁₋₆ alkoxy;

(ii) C₃₋₇ cycloalkyl or C₄₋₁₀ alkylcycloalkyl, all optionally substituted with carboxyl, (C₁₋₆ alkoxy)carbonyl, amino or amido.

8. A compound of formula I according to claim 2, wherein **B** is a C₆ or C₁₀ aryl optionally substituted with C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkanoyl, hydroxy, hydroxyalkyl, halo, haloalkyl, nitro, cyano, cyanoalkyl, amido, (lower alkyl)amide,

or amino optionally mono- or di-substituted with C₁₋₆ alkyl.


9. A compound of formula I according to claim 2, wherein **B** is Het optionally substituted with C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkanoyl, hydroxy, halo, amido, (lower alkyl)amide, or amino optionally mono- or di-substituted with C₁₋₆ alkyl.
10. A compound of formula I according to claim 4, wherein **B** is an acyl derivative of formula **R₄-C(O)-** wherein **R₄** is
- (i) C₁₋₁₀ alkyl optionally substituted with carboxyl, hydroxy or C₁₋₆ alkoxy; or
 - (ii) C₃₋₇ cycloalkyl or C₄₋₁₀ alkylcycloalkyl, both optionally substituted with hydroxy, carboxyl, (C₁₋₆ alkoxy)carbonyl, or
 - (iv) C₆ or C₁₀ aryl or C₇₋₁₆ aralkyl, all optionally substituted with C₁₋₆ alkyl, hydroxy, or (v) Het optionally substituted with C₁₋₆ alkyl, hydroxy, amido or amino.
11. A compound of formula I according to claim 5, wherein **B** is a carboxyl derivative of formula **R₄-O-C(O)-**, wherein **R₄** is
- (i) C₁₋₁₀ alkyl optionally substituted with carboxyl, C₁₋₆ alkanoyl, hydroxy, C₁₋₆ alkoxy or amido, (lower alkyl)amide, amino optionally mono- or di-substituted with C₁₋₆ alkyl;
 - (ii) C₃₋₇ cycloalkyl, C₄₋₁₀ alkylcycloalkyl, all optionally substituted with carboxyl, (C₁₋₆ alkoxy)carbonyl, amido, (lower alkyl)amide, amino optionally mono- or di-substituted with C₁₋₆ alkyl, or
 - (iv) C₆ or C₁₀ aryl or C₇₋₁₆ aralkyl, all optionally substituted with C₁₋₆ alkyl, hydroxy, amino optionally substituted with C₁₋₆ alkyl; or
 - (v) Het or (lower alkyl)-Het, both optionally substituted with C₁₋₆ alkyl, hydroxy, amido, or amino optionally mono-substituted with C₁₋₆ alkyl.
12. A compound of formula I according to claim 6, wherein **B** is an amide derivative of formula **R₄-N(R₅)-C(O)-** wherein **R₄** is
- (i) C₁₋₁₀ alkyl optionally substituted with carboxyl, C₁₋₆ alkanoyl, hydroxy, C₁₋₆ alkoxy, amido, (lower alkyl)amide, amino optionally mono- or di-substituted with C₁₋₆ alkyl;
 - (ii) C₃₋₇ cycloalkyl or C₄₋₁₀ alkylcycloalkyl, all optionally substituted with carboxyl, (C₁₋₆ alkoxy)carbonyl, amido, (lower alkyl)amide, amino optionally mono- or di-substituted with C₁₋₆ alkyl;

- (iii) amino optionally mono- or di-substituted with C_{1-3} alkyl, or
- (iv) C_6 or C_{10} aryl or C_{7-16} aralkyl, all optionally substituted with C_{1-6} alkyl, hydroxy, amino or amido optionally substituted with C_{1-6} alkyl; or
- (v) Het optionally substituted with C_{1-6} alkyl, hydroxy, amino or amido,


and R_5 is H.

13. A compound of formula I according to claim 7, wherein **B** is a thioamide derivative of formula $R_4-NH-C(S)-$; wherein R_4 is (i) C_{1-10} alkyl; or (ii) C_{3-7} cycloalkyl.
14. A compound of formula I according to claim 12, wherein **B** is an amide derivative of formula $R_4-NH-C(O)-$ wherein R_4 is
 - (i) C_{1-10} alkyl optionally substituted with carboxyl, C_{1-6} alkanoyl, hydroxy, C_{1-6} alkoxy amido, (lower alkyl)amide, amino optionally mono- or di-substituted with C_{1-6} alkyl;
 - (ii) C_{3-7} cycloalkyl or C_{4-10} alkylcycloalkyl, all optionally substituted with carboxyl, (C_{1-6} alkoxy)carbonyl, amido, (lower alkyl)amide, amino optionally mono- or di-substituted with C_{1-6} alkyl;
 - (iv) C_6 or C_{10} aryl or C_{7-16} aralkyl optionally substituted with C_{1-6} alkyl, hydroxy, amino or amido.

15. A compound of formula I according to claim 1, wherein **B** is



16. A compound of formula I according to claim 1, wherein **Y** is H or methyl.
17. A compound of formula I according to claim 16, wherein **Y** is H.
18. A compound of formula I according to claim 1, wherein R^3 is C_{1-8} alkyl, C_{3-7} cycloalkyl, or C_{4-10} alkylcycloalkyl, all optionally substituted with hydroxy, C_{1-6} alkoxy, C_{1-6} thioalkyl, acetamido, C_6 or C_{10} aryl, or C_{7-16} aralkyl,.
19. A compound of formula I according to claim 18, wherein R^3 is the side chain of Tbg, Ile, Val, Chg or:



20. A compound of formula I according to claim 19, wherein R^3 is the side chain of


Tbg, Chg or Val.

21. A compound of formula I according to claim 1, wherein R^2 is S- R_{20} or O- R_{20} wherein R_{20} is a C_6 or C_{10} aryl, C_{7-16} aralkyl, Het or $-CH_2$ -Het, all optionally mono-, di- or tri-substituted with R_{21} , wherein

R_{21} is C_{1-6} alkyl; C_{1-6} alkoxy; lower thioalkyl; amino or amido optionally mono- or di-substituted with C_{1-6} alkyl, C_6 or C_{10} aryl, C_{7-16} aralkyl, Het or (lower alkyl)-Het; NO_2 ; OH; halo; trifluoromethyl; carboxyl; C_6 or C_{10} aryl, C_{7-16} aralkyl, or Het, said aryl, aralkyl or Het being optionally substituted with R_{22} , wherein


R_{22} is C_{1-6} alkyl; C_{3-7} cycloalkyl; C_{1-6} alkoxy; amino; mono- or di-(lower alkyl)amino; (lower alkyl)amide; sulfonylalkyl; NO_2 ; OH; halo; trifluoromethyl; carboxyl or Het.

22. A compound of formula I according to claim 21, wherein R_{21} is C_{1-6} alkyl; C_{1-6} alkoxy; amino; di(lower alkyl)amino; (lower alkyl)amide; C_6 or C_{10} aryl, or Het, said aryl or Het being optionally substituted with R_{22} , wherein R_{22} is C_{1-6} alkyl; C_{3-7} cycloalkyl; C_{1-6} alkoxy; amino; mono- or di(lower alkyl)amino; amido; (lower alkyl)amide; halo; trifluoromethyl or Het.
23. A compound of formula I according to claim 22, wherein R_{22} is C_{1-6} alkyl; C_{1-6} alkoxy; halo; amino optionally mono- or di-substituted with lower alkyl; amido; (lower alkyl)amide; or Het.
24. A compound of formula I according to claim 23, wherein R_{22} is methyl; ethyl; isopropyl; tert-butyl; methoxy; chloro; amino optionally mono- or di-substituted with lower alkyl; amido, (lower alkyl)amide; or (lower alkyl) 2-thiazole.
25. A compound of formula I according to claim 21, wherein R^2 is selected from the group consisting of:




26. A compound of formula I according to claim 21, wherein R^2 is 1-naphthylmethoxy; 2-naphthylmethoxy; benzyloxy, 1-naphthyl; 2-naphthyl; or quinolinyl, unsubstituted, mono- or di-substituted with R_{21} as defined in claim 21.

27. A compound of formula I according to claim 26, wherein R^2 is 1-naphtylmethoxy; or quinolinoxy unsubstituted, mono- or di-substituted with R_{21} as defined in claim 26.
28. A compound of formula I according to claim 27, wherein R^2 is selected from the group consisting of:




29. A compound of formula I according to claim 26, wherein R^2 is :




wherein R_{21A} is C_{1-6} alkyl; C_{1-6} alkoxy; lower thioalkyl; halo; amino optionally mono-substituted with C_{1-6} alkyl; or C_6 , C_{10} aryl, C_{7-16} aralkyl, or Het, said aryl, aralkyl or Het optionally substituted with R_{22} wherein R_{22} is C_{1-6} alkyl, C_{1-6} alkoxy, amido, (lower alkyl)amide, amino optionally mono- or di-substituted with C_{1-6} alkyl, or Het; and


R_{21B} is C_{1-6} alkyl, C_{1-6} alkoxy, amino, di(lower alkyl)amino, (lower alkyl)amide, NO_2 , OH, halo, trifluoromethyl, or carboxyl.

30. A compound of formula I according to claim 29, wherein R_{21A} is C_6 , C_{10} aryl or Het, all optionally substituted with R_{22} as defined in claim 29.
31. A compound of formula I according to claim 30, wherein R_{21A} is selected from the group consisting of:






32. A compound of formula I according to claim 21, wherein R^2 is:



wherein R_{22A} is C_{1-6} alkyl; C_{1-6} alkoxy; or halo; and R_{21B} is C_{1-6} alkyl, C_{1-6} alkoxy, amino, di(lower alkyl)amino, (lower alkyl)amide, NO_2 , OH, halo, trifluoromethyl, or carboxyl.


33. A compound of formula I according to claim 29, wherein R^2 is:




wherein R_{22B} is C_{1-6} alkyl, amino optionally mono-substituted with C_{1-6} alkyl, amido, or (lower alkyl)amide; ; and R_{21B} is C_{1-6} alkyl, C_{1-6} alkoxy, amino, di(lower alkyl)amino, (lower alkyl)amide, NO_2 , OH, halo, trifluoromethyl, or carboxyl.

34. A compound of formula I according to claim 32 or 33, wherein R_{21B} is C_{1-6} alkoxy, or di(lower alkyl)amino.
35. A compound of formula I according to claim ~~32~~ or 33, wherein R_{21B} is methoxy.
36. A compound of formula I according to claim 1, wherein R^1 is H, C_{1-3} alkyl, C_{3-5} cycloalkyl, or C_{2-4} alkenyl, all optionally substituted with halo.

T,1370




37. A compound of formula I according to claim 36, wherein **P1** is and **R¹** is ethyl, vinyl, cyclopropyl, 1 or 2-bromoethyl or 1 or 2-bromovinyl.
38. A compound of formula I according to claim 37, wherein **R¹** is vinyl.
39. A compound of formula I according to claim 37, wherein **R¹** at carbon 2 is orientated *syn* to the carbonyl at position 1, represented by the radical:




T,1371

40. A compound of formula I according to claim 37, wherein **R¹** at position 2 is orientated *anti* to the carbonyl at position 1, represented by the radical:



T,1372


41. A compound of formula I according to claim 37, wherein carbon 1 has the *R* configuration:



T,1373

42. An optical isomer of a compound of formula I according to claim 41, wherein said **R¹** substituent and the carbonyl in a *syn* orientation in the following absolute configuration:

T,1380



43. A compound of formula I according to claim 42, wherein R^1 is ethyl, hence the asymmetric carbon atoms at positions 1 and 2 have the R,R configuration.
44. A compound of formula I according to claim 42, wherein R^1 is vinyl, hence the asymmetric carbon atoms at positions 1 and 2 have the R,S configuration.
45. A compound of formula I according to claim 1, wherein
- B** is a C_6 or C_{10} aryl or C_{7-16} aralkyl, all optionally substituted with C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkanoyl, hydroxy, hydroxyalkyl, halo, haloalkyl, nitro, cyano, cyanoalkyl, amido, (lower alkyl)amido, or amino optionally substituted with C_{1-6} alkyl; or
- Het or (lower alkyl)-Het, all optionally substituted with C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkanoyl, hydroxy, hydroxyalkyl, halo, haloalkyl, nitro, cyano, cyanoalkyl, amido, (lower alkyl)amido, or amino optionally substituted with C_{1-6} alkyl, or
- B** is R_4-SO_2 wherein R_4 is preferably amido; (lower alkyl)amide; C_6 or C_{10} aryl, C_{7-14} aralkyl or Het, all optionally substituted with C_{1-6} alkyl, or
- B** is an acyl derivative of formula $R_4-C(O)-$ wherein R_4 is
- (i) C_{1-10} alkyl optionally substituted with carboxyl, hydroxy or C_{1-6} alkoxy, amido, (lower alkyl)amide, or amino optionally mono- or di-substituted with C_{1-6} alkyl;
 - (ii) C_{3-7} cycloalkyl or C_{4-10} alkylcycloalkyl, both optionally substituted with hydroxy, carboxyl, (C_{1-6} alkoxy)carbonyl, amido, (lower alkyl)amide, or amino optionally mono- or di-substituted with C_{1-6} alkyl;
 - (iv) C_6 or C_{10} aryl or C_{7-16} aralkyl, all optionally substituted with C_{1-6} alkyl, hydroxy, amido, (lower alkyl)amide, or amino optionally substituted with C_{1-6} alkyl;
 - (v) Het or (lower alkyl)-Het, both optionally substituted with C_{1-6} alkyl, hydroxy, amino optionally substituted with C_{1-6} alkyl, amido, (lower alkyl)amide, or amino optionally substituted with C_{1-6} alkyl, or

B is a carboxyl derivative of formula $\mathbf{R}_4\text{-O-C(O)-}$, wherein \mathbf{R}_4 is

- (i) C_{1-10} alkyl optionally substituted with carboxyl, C_{1-6} alkanoyl, hydroxy, C_{1-6} alkoxy, amino optionally mono- or di-substituted with C_{1-6} alkyl, amido or (lower alkyl)amide;
- (ii) C_{3-7} cycloalkyl, C_{4-10} alkylcycloalkyl, all optionally substituted with carboxyl, (C_{1-6} alkoxy)carbonyl, amino optionally mono- or di-substituted with C_{1-6} alkyl, amido or (lower alkyl)amide;
- (iv) C_6 or C_{10} aryl or C_{7-16} aralkyl optionally substituted with C_{1-6} alkyl, hydroxy, amido, (lower alkyl)amido, or amino optionally mono- or di-substituted with C_{1-6} alkyl; or
- (v) Het or (lower alkyl)-Het, both optionally substituted with C_{1-6} alkyl, hydroxy, amino optionally mono- or di-substituted with C_{1-6} alkyl, amido or (lower alkyl)amido, or

B is an amide derivative of formula $\mathbf{R}_4\text{-N(R}_5\text{)-C(O)-}$ wherein \mathbf{R}_4 is

- (i) C_{1-10} alkyl optionally substituted with carboxyl, C_{1-6} alkanoyl, hydroxy, C_{1-6} alkoxy, amido, (lower alkyl)amido, or amino optionally mono- or di-substituted with C_{1-6} alkyl;
- (ii) C_{3-7} cycloalkyl or C_{4-10} alkylcycloalkyl, all optionally substituted with carboxyl, (C_{1-6} alkoxy)carbonyl, amido, (lower alkyl)amido, or amino optionally mono- or di-substituted with C_{1-6} alkyl;
- (iii) amino optionally mono- or di-substituted with C_{1-3} alkyl;
- (iv) C_6 or C_{10} aryl or C_{7-16} aralkyl, all optionally substituted with C_{1-6} alkyl, hydroxy, amido, (lower alkyl)amide, or amino optionally substituted with C_{1-6} alkyl; or
- (v) Het or (lower alkyl)-Het, both optionally substituted with C_{1-6} alkyl, hydroxy, amino optionally substituted with C_{1-6} alkyl, amido or (lower alkyl)amide; and

\mathbf{R}_5 is H or methyl, or

B is thioamide derivative of formula $\mathbf{R}_4\text{-NH-C(S)-}$; wherein \mathbf{R}_4 is

- (i) C_{1-10} alkyl optionally substituted with carboxyl, C_{1-6} alkanoyl or C_{1-6} alkoxy;
- (ii) C_{3-7} cycloalkyl or C_{4-10} alkylcycloalkyl, all optionally substituted with

carboxyl, (C₁₋₆ alkoxy)carbonyl, amino or amido;

Y is H or methyl;


R³ is C₁₋₈ alkyl, C₃₋₇ cycloalkyl, or C₄₋₁₀ alkylcycloalkyl, all optionally substituted with hydroxy, C₁₋₆ alkoxy, C₁₋₆ thioalkyl, acetamido, C₆ or C₁₀ aryl, or C₇₋₁₆ aralkyl;

R² is S-R₂₀ or O-R₂₀ wherein R₂₀ is a C₆ or C₁₀ aryl, C₇₋₁₆ aralkyl, Het or -CH₂-Het, all optionally mono-, di- or tri-substituted with R₂₁, wherein


R₂₁ is C₁₋₆ alkyl; C₁₋₆ alkoxy; lower thioalkyl; amino or amido optionally mono- or di-substituted with C₁₋₆ alkyl, C₆ or C₁₀ aryl, C₇₋₁₆ aralkyl, Het or (lower alkyl)-Het; NO₂; OH; halo; trifluoromethyl; carboxyl; C₆ or C₁₀ aryl, C₇₋₁₆ aralkyl, or Het, said aryl, aralkyl or Het being optionally substituted with R₂₂, wherein

R₂₂ is C₁₋₆ alkyl; C₃₋₇ cycloalkyl; C₁₋₆ alkoxy; amino; mono- or di-(lower alkyl)amino; (lower alkyl)amide; sulfonylalkyl; NO₂; OH; halo; trifluoromethyl; carboxyl or Het; or

R² is selected from the group consisting of:




or R² is 1-naphthylmethoxy; 2-naphthylmethoxy; benzyloxy, 1-naphthyloxy; 2-naphthyloxy; or quinolinoxy unsubstituted, mono- or di-substituted with R₂₁ as defined above; and



P1 is:

wherein R¹ is H, C₁₋₃ alkyl, C₃₋₅ cycloalkyl, or C₂₋₄ alkenyl optionally substituted with halo, and said R¹ at carbon 2 is orientated *syn* to the carbonyl at position 1, represented by the radical:

T₁1410

or a pharmaceutically acceptable salt or ester thereof.

46. A compound of formula I according to claim 45, wherein **B** is a C₆ or C₁₀ aryl optionally substituted with C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkanoyl, hydroxy, hydroxyalkyl, halo, haloalkyl, nitro, cyano, cyanoalkyl, amido, (lower alkyl)amide, or amino optionally mono- or di-substituted with C₁₋₆ alkyl; or **B** is Het optionally substituted with C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkanoyl, hydroxy, halo, amido, (lower alkyl)amide, or amino optionally mono- or di-substituted with C₁₋₆ alkyl; or **B** is R₄-SO₂ wherein R₄ is C₆ or C₁₀ aryl, a C₇₋₁₄ aralkyl or Het all optionally substituted with C₁₋₆ alkyl; amido, (lower alkyl)amide; **B** is an acyl derivative of formula R₄-C(O)- wherein R₄ is

- (i) C₁₋₁₀ alkyl optionally substituted with carboxyl, hydroxy or C₁₋₆ alkoxy; or
- (ii) C₃₋₇ cycloalkyl or C₄₋₁₀ alkylcycloalkyl, both optionally substituted with hydroxy, carboxyl, (C₁₋₆ alkoxy)carbonyl; or
- (iv) C₆ or C₁₀ aryl or C₇₋₁₆ aralkyl, all optionally substituted with C₁₋₆ alkyl, hydroxy; or
- (v) Het optionally substituted with C₁₋₆ alkyl, hydroxy, amido or amino;

or **B** is a carboxyl derivative of formula R₄-O-C(O)-, wherein R₄ is

- (i) C₁₋₁₀ alkyl optionally substituted with carboxyl, C₁₋₆ alkanoyl, hydroxy, C₁₋₆ alkoxy or amido, (lower alkyl)amide, amino optionally mono- or di-substituted with C₁₋₆ alkyl;
- (ii) C₃₋₇ cycloalkyl, C₄₋₁₀ alkylcycloalkyl, all optionally substituted with carboxyl, (C₁₋₆ alkoxy)carbonyl, amido, (lower alkyl)amide, amino optionally mono- or di-substituted with C₁₋₆ alkyl; or
- (iv) C₆ or C₁₀ aryl or C₇₋₁₆ aralkyl, all optionally substituted with C₁₋₆ alkyl, hydroxy, amino optionally substituted with C₁₋₆ alkyl; or
- (v) Het or (lower alkyl)-Het, both optionally substituted with C₁₋₆ alkyl,

hydroxy, amido, or amino optionally mono-substituted with C₁₋₆ alkyl;
or **B** is an amide derivative of formula **R**₄-N(**R**₅)-C(O)- wherein **R**₄ is


- (i) C₁₋₁₀ alkyl optionally substituted with carboxyl, C₁₋₆ alkanoyl, hydroxy, C₁₋₆ alkoxy, amido, (lower alkyl)amide, amino optionally mono- or di-substituted with C₁₋₆ alkyl;
- (ii) C₃₋₇ cycloalkyl or C₄₋₁₀ alkylcycloalkyl, all optionally substituted with carboxyl, (C₁₋₆ alkoxy)carbonyl, amido, (lower alkyl)amide, amino optionally mono- or di-substituted with C₁₋₆ alkyl; and **R**₅ is H or methyl; or
- R**₄ is (iii) amino optionally mono- or di-substituted with C₁₋₃ alkyl; or
- (iv) C₆ or C₁₀ aryl or C₇₋₁₆ aralkyl, all optionally substituted with C₁₋₆ alkyl, hydroxy, amino or amido optionally substituted with C₁₋₆ alkyl; or
- (v) Het optionally substituted with C₁₋₆ alkyl, hydroxy, amino or amido; or

B is a thioamide derivative of formula **R**₄-NH-C(S)-; wherein **R**₄ is:

- (i) C₁₋₁₀ alkyl; or (ii) C₃₋₇ cycloalkyl; or


Y is H;

R³ is the side chain of Tbg, Ile, Val, Chg or:




R₂ is 1-naphthylmethoxy; or quinolinoxyl unsubstituted, mono- or di-substituted with **R**₂₁ as defined above, or

R₂ is :



wherein **R**_{21A} is C₁₋₆ alkyl; C₁₋₆ alkoxy; C₆, C₁₀ aryl or Het; lower thioalkyl; halo; amino optionally mono-substituted with C₁₋₆ alkyl; or C₆, C₁₀ aryl, C₇₋₁₆ aralkyl or Het, optionally substituted with **R**₂₂ wherein **R**₂₂ is C₁₋₆ alkyl, C₁₋₆ alkoxy, amido, (lower alkyl)amide, amino optionally mono- or di-substituted with C₁₋₆ alkyl, or Het; and **R**_{21B} is C₁₋₆ alkyl, C₁₋₆ alkoxy, amino, di(lower alkyl)amino, (lower alkyl)amide, NO₂, OH, halo, trifluoromethyl, or carboxyl;

P1 is:



R^1 is ethyl, vinyl, cyclopropyl, 1 or 2-bromoethyl or 1 or 2-bromovinyl.


47. A compound of formula I according to claim 46, wherein

B is an amide derivative of formula $R_4\text{-NH-C(O)-}$ wherein R_4 is

- i) C_{1-10} alkyl optionally substituted with carboxyl, C_{1-6} alkanoyl, hydroxy, C_{1-6} alkoxy amido, (lower alkyl)amide, amino optionally mono- or di-substituted with C_{1-6} alkyl;
- (ii) C_{3-7} cycloalkyl or C_{4-10} alkylcycloalkyl, all optionally substituted with carboxyl, (C_{1-6} alkoxy)carbonyl, amido, (lower alkyl)amide, amino optionally mono- or di-substituted with C_{1-6} alkyl;
- (iv) C_6 or C_{10} aryl or C_{7-16} aralkyl optionally substituted with C_{1-6} alkyl, hydroxy, amino or amido;

R^3 is the side chain of Tbg, Chg or Val;


R^2 is:



wherein R_{22A} is C_{1-6} alkyl; C_{1-6} alkoxy; or halo; R_{22B} is C_{1-6} alkyl, amino optionally mono-substituted with C_{1-6} alkyl, amido, or (lower alkyl)amide; and R_{21B} is C_{1-6} alkyl, C_{1-6} alkoxy, amino, di(lower alkyl)amino, (lower alkyl)amide, NO_2 , OH, halo, trifluoromethyl, or carboxyl;


and **P1** is:

T,1440



48. A compound according to claim 45 represented by the formula:





T,1441



wherein B , R_3 , R_2 are as defined below:


T,1442

| Tab 1 Cpd# | B | R^3 | R^2 |
|---------------|-----|-------|----------------------------------|
| 101 | Boc | cHex | -O-CH ₂ -1-naphthyl ; |
| 102 | | cHex | -O-CH ₂ -1-naphthyl ; |
| 103 | | cHex | -O-CH ₂ -1-naphthyl ; |
| 104 | | cHex | -O-CH ₂ -1-naphthyl ; |
| 105 | | cHex | -O-CH ₂ -1-naphthyl ; |
| 106 | Boc | cHex | ; |
| 107 | | cHex | -O-CH ₂ -1-naphthyl ; |

| Tab 1 Cpd# | B | R ³ | R ² |
|---------------|--------|----------------|---|
| 108 | Boc | iPr |  |
| 109 | acetyl | cHex |  |
| 110 | Boc | <i>i</i> -Pr |  |
| and 111 | Boc | <i>t</i> -Bu |  |

49. Compound # 111 according to claim 48.











50. A compound according to claim 45 represented by the formula:



wherein B, R³, R², R¹ are as defined below:

T₁1451



| Table 2 Cpd # | B | R ³ | R ² | R ¹ anti to carboxy |
|------------------|-----|----------------|--------------------------------|-----------------------------------|
| 201 | Boc | cyclohexyl | -O-CH ₂ -1-naphthyl | ethyl (one isomer) |
| 202 | Boc | cyclohexyl | -O-CH ₂ -1-naphthyl | ethyl (other isomer) |

| Table 3 Cpd # | B | R ³ | R ² | R ¹ <i>syn</i> to carboxyl vinyl | |
|------------------|--------|----------------|---|--|---|
| 308 | Boc | cHex |  | vinyl | ; |
| 309 | Boc | cHex |  | vinyl | ; |
| 310 | Boc | cHex |  | vinyl | ; |
| 311 | Boc | cHex |  | vinyl | ; |
| 312 | Boc | cHex |  | vinyl | ; |
| 313 | Boc | cHex |  | vinyl | ; |
| 314 | Boc | cHex |  | vinyl | ; |
| 315 | Boc | cHex |  | vinyl | ; |
| 316 | Acetyl | cHex |  | vinyl | ; |
| 317 | Boc | cHex |  | vinyl | ; |

- 147 -


- 148 -

149

| Table 3 Cpd # | B | R ³ | R ² | R ¹ syn to carbox yl vinyl |
|------------------|---|----------------|--|---|
| and 334 |  | <i>t</i> -Bu |  | . |

53. A compound according to claim 52, selected from the group consisting of compound #: 307, 314, 317, 319, 321, 324, 325, 326, 327, 329, 331, 332, 333, and 334.

54. A compound according to claim 45 represented by the formula:




wherein **B**, **R³**, **R²** and **R¹** are as defined below:

T,1511

| Table 4 Cpd # | B | R ³ | R ² | R ¹ |
|------------------|-----|----------------|----------------|-------------------------|
| 401 | Boc | <i>i</i> -Pr | | H ; |
| 402 | Boc | <i>t</i> -Bu | | H ; |
| 403 | Boc | <i>t</i> -Bu | | H ; |
| 404 | Boc | <i>t</i> -Bu | | 3-(=CH ₂) ; |
| 405 | Boc | <i>t</i> -Bu | | 2-vinyl ; |
| and 406 | Boc | <i>t</i> -Bu | | 2-Et . |


55. A compound according to claim 54, selected from the group consisting of compound #: **403**, **405**, and **406**.
56. A compound according to claim 45 represented by the formula:

T₁1520wherein R^3 is as defined below:T₁1521

| Table 5 Cpd # 501 | R^3 | Table 5 Cpd # 507 | R^3 |
|-------------------------|--------------|-------------------------|-------|
| | <i>t</i> -Bu | | |
| 502 | H | 508 | |
| 503 | | 509 | |
| 504 | | 510 | |
| 505 | | and 511 | |
| 506 | | | |

57. A compound according to claim 56, selected from the group consisting of compound #: 501, 509, and 510.
58. A compound according to claim 46 represented by the formula:










T, 1530



wherein R^3 , R_{21A} and R_{21B} are as defined below:


| Table 6 Cpd # | R^3 | R_{21A} | R_{21B} |
|------------------|-------------------------------|-----------|----------------------------|
| 601 | <i>i</i> -Pr | Ph | 7-OMe ; |
| 602 | <i>t</i> -Bu | Ph | 8-OMe, ; 7-OMe |
| 603 | <i>i</i> -Pr | Ph | 7-ethyl ; |
| 604 | <i>t</i> -Bu | -- | 7-OMe ; |
| 605 | <i>t</i> -Bu | Ph | 7-O- <i>i</i> Pr ; |
| 606 | <i>t</i> -Bu | -- | 7-Cl ; |
| 607 | <i>i</i> Pr | -- | 7-Cl ; |
| 608 | CH ₂ - <i>i</i> Pr | -- | 7-Cl ; |
| 609 | <i>t</i> -Bu | | -- ; |
| 610 | <i>t</i> -Bu | Cl | -- ; |
| 611 | <i>t</i> -Bu | Ph | 7- ; N(Me) ₂ |
| 612 | <i>t</i> -Bu | | -- ; |
| 613 | <i>t</i> -Bu | | -- ; |
| 614 | <i>t</i> -Bu | | -- ; |
| 615 | <i>t</i> -Bu | -- | 7- ; N(Me) ₂ |
| 616 | <i>t</i> -Bu | | -- ; |

T, 1531

| Table 6 Cpd # | R ³ | R _{21A} | R _{21B} |
|------------------|----------------|--|----------------------------|
| 617 | <i>t</i> -Bu |  | -- ; |
| 618 | <i>t</i> -Bu |  | -- ; |
| 619 | <i>t</i> -Bu |  | -- ; |
| 620 | <i>t</i> -Bu |  | -- ; |
| 621 | <i>t</i> -Bu |  | -- ; |
| 622 | <i>t</i> -Bu |  | -- ; |
| 623 | <i>t</i> -Bu | MeO- | -- ; |
| 624 | <i>t</i> -Bu | (Me) ₂ N- | -- ; |
| 625 | <i>t</i> -Bu | Ph | 7-S(Me) ; |
| 626 | <i>t</i> -Bu | Ph | 7-Br ; |
| 627 | <i>t</i> -Bu | Ph | 7-F ; |
| 628 | <i>t</i> -Bu |  | 7- N(Me) ₂ ; |
| 629 | <i>t</i> -Bu |  | 7- N(Me) ₂ ; |
| and 630 | <i>t</i> -Bu |  | 7-N(Et) ₂ . |

59. A compound according to claim 58, selected from the group consisting of compound #: 601, 602, 603, 604, 605, 606, 607, 610, 611, 612, 615, 616, 617, 620, 621, 622, 625, 626, 627, 628, 629, and 630.
60. A compound according to claim 46 represented by the formula:







T,ISSO

wherein R^3 and R_{21A} are as defined below:


| Table 7 Cpd # | R^3 | R_{21A} | |
|------------------|--------------|----------------------|---|
| 701 | <i>t</i> -Bu | | ; |
| 702 | <i>t</i> -Bu | | ; |
| 703 | <i>t</i> -Bu | | ; |
| 704 | <i>t</i> -Bu | | ; |
| 705 | <i>t</i> -Bu | | ; |
| 706 | <i>t</i> -Bu | | ; |
| 707 | <i>t</i> -Bu | | ; |
| 708 | <i>t</i> -Bu | Ph-N(Me)- | ; |
| 709 | <i>t</i> -Bu | | ; |
| 710 | <i>t</i> -Bu | HOOC- | ; |
| 711 | <i>t</i> -Bu | | ; |
| 712 | <i>t</i> -Bu | (Me) ₂ N- | ; |
| 713 | <i>t</i> -Bu | | ; |
| 714 | <i>t</i> -Bu | | ; |
| 715 | <i>t</i> -Bu | | ; |

- 155 -

156


| Table 7 Cpd # | R ³ | R _{21A} | |
|------------------|----------------|---|---|
| 730 | <i>t</i> -Bu |  | ; |
| 731 | <i>t</i> -Bu |  | ; |
| 732 | <i>t</i> -Bu |  | ; |
| 733 | <i>t</i> -Bu |  | ; |
| 734 | <i>t</i> -Bu |  | ; |
| 735 | <i>t</i> -Bu |  | ; |
| 736 | <i>t</i> -Bu | <i>t</i> -Bu | ; |
| and 737 | <i>t</i> -Bu | CHex | . |













61. A compound according to claim 60, selected from the group consisting of compound #: 701, 702, 703, 704, 705, 706, 707, 708, 709, and 711 to 737.
62. A compound according to claim 45 represented by the formula:




























wherein B, R³, and R₂₂ are as defined below:















T₁₅₇₁











| Table 8 Cpd # | B | R ³ | R ₂₂ | |
|------------------|---|----------------|-----------------|---|
| 801 |  | <i>t</i> -Bu | -- | ; |

| Table 8 Cpd # | B | R ³ | R ₂₂ | |
|------------------|---|----------------|-----------------|---|
| 802 |  | <i>t</i> -Bu | -- | ; |
| 803 |  | <i>t</i> -Bu | -- | ; |
| 804 |  | <i>t</i> -Bu | -- | ; |
| 805 | Ac | <i>t</i> -Bu | -- | ; |
| 806 |  | <i>t</i> -Bu | -- | ; |
| 807 |  | <i>t</i> -Bu | -- | ; |
| 808 |  | <i>t</i> -Bu | -- | ; |
| 809 |  | <i>i</i> -Pr | -- | ; |
| 810 |  | <i>t</i> -Bu | -- | ; |
| 811 | Boc | <i>t</i> -Bu | 4-Cl | ; |
| 812 |  | <i>t</i> -Bu | -- | ; |
| 813 |  | <i>t</i> -Bu | -- | ; |
| 814 | Boc | <i>t</i> -Bu | 2-Cl | ; |
| 815 | Boc | <i>t</i> -Bu | 3-Cl | ; |
| 816 |  | <i>t</i> -Bu | -- | ; |
| 817 |  | <i>t</i> -Bu | -- | ; |


| Table 8 Cpd # | B | R ³ | R ₂₂ | |
|------------------|---|----------------|-----------------|---|
| 818 |  | <i>t</i> -Bu | -- | ; |
| 819 |  | <i>i</i> -Pr | -- | ; |
| 820 |  | <i>i</i> -Pr | -- | ; |
| 821 |  | <i>i</i> -Pr | -- | ; |
| 822 |  | <i>i</i> -Pr | -- | ; |
| 823 | Boc | <i>t</i> -Bu | 2-OMe | ; |
| 824 | Boc | <i>t</i> -Bu | 3-OMe | ; |
| 825 | Boc | <i>t</i> -Bu | 4-OMe | ; |
| 826 |  | <i>i</i> -Pr | -- | ; |
| 827 |  | <i>t</i> -Bu | -- | ; |
| 828 |  | <i>i</i> -Pr | -- | ; |
| 829 |  | <i>t</i> -Bu | -- | ; |
| 830 |  | <i>t</i> -Bu | -- | ; |
| 831 |  | <i>t</i> -Bu | -- | ; |
| 832 |  | <i>t</i> -Bu | -- | ; |
| 833 |  | <i>t</i> -Bu | -- | ; |

| Table 8 Cpd # | B | R ³ | R ₂₂ | |
|------------------|---|--|-----------------|---|
| 834 |  | <i>i</i> -Pr | -- | ; |
| 835 |  | <i>t</i> -Bu | -- | ; |
| 836 |  | <i>i</i> -Pr | -- | ; |
| 837 |  | <i>i</i> -Pr | -- | ; |
| 838 |  | <i>i</i> -Pr | -- | ; |
| 839 |  | <i>i</i> -Pr | -- | ; |
| 840 |  | <i>i</i> -Pr | -- | ; |
| 841 | Boc | <i>t</i> -Bu | 2-Me | ; |
| 842 | Boc | <i>t</i> -Bu | 3-Me | ; |
| 843 | Boc | <i>t</i> -Bu | 4-Me | ; |
| 844 |  | <i>t</i> -Bu | 4-OMe | ; |
| 845 |  | <i>i</i> -Pr | -- | ; |
| 846 |  | <i>i</i> -Pr | -- | ; |
| 847 | Boc | cHex | -- | ; |
| 848 | Boc |  | -- | ; |
| 849 | Boc |  | -- | ; |

| Table 8 Cpd # | B | R ³ | R ₂₂ | |
|------------------|---|--|-----------------|---|
| 850 | Boc |  | -- | ; |
| 851 | Boc |  | -- | ; |
| 852 | Boc |  | -- | ; |
| 853 | Boc |  | -- | ; |
| 854 |  | <i>i</i> -Pr | -- | ; |
| 855 |  | <i>i</i> -Pr | -- | ; |
| 856 |  | <i>i</i> -Pr | -- | ; |
| 857 |  | <i>t</i> -Bu | -- | ; |
| 858 |  | <i>t</i> -Bu | -- | ; |
| 859 |  | <i>i</i> -Pr | -- | ; |
| 860 |  | <i>i</i> -Pr | -- | ; |
| 861 |  | <i>i</i> -Pr | -- | ; |
| 862 |  | <i>i</i> -Pr | -- | ; |
| 863 |  | <i>i</i> -Pr | -- | ; |

| Table 8 Cpd # | B | R ³ | R ₂₂ | |
|------------------|---|----------------|-----------------|---|
| 864 |  | <i>i</i> -Pr | -- | ; |
| 865 |  | <i>t</i> -Bu | -- | ; |
| 866 |  | <i>t</i> -Bu | -- | ; |
| 867 |  | <i>t</i> -Bu | -- | ; |
| 868 |  | <i>t</i> -Bu | -- | ; |
| 869 |  | <i>t</i> -Bu | -- | ; |
| 870 |  | <i>t</i> -Bu | -- | ; |
| 871 |  | <i>t</i> -Bu | -- | ; |
| 872 |  | <i>t</i> -Bu | -- | ; |
| and 873 |  | <i>t</i> -Bu | -- | . |

63. A compound according to claim 62, selected from the group consisting of compound #: 801 to 825, 827 to 858, and 860 to 873.
64. A compound according to claim 45 represented by the formula:



wherein **B** is as defined below:

T, 1630

Table 9

Cpd #


901

B

Boc


;

902




;

903




;

904




;

905




;

906




;

907




;

908




;

909




;

910




;

911



;


912



;

| Table 9 Cpd # | B | |
|------------------|---|---|
| 913 | | ; |
| 914 | | ; |
| 915 | | ; |
| and 916 | | . |

65. A compound according to claim 45 represented by the formula:



wherein B, X, R³, z and R_{21B} are as defined below:

T₁₆₄₁


| Table 10 Cpd # | B-X- | R ³ | Z | R _{21B} |
|-------------------|-----------|----------------|---|------------------|
| 1001 | Ph-N(Me)- | <i>i</i> -Pr | O | H; |
| 1002 | Boc-NH- | <i>t</i> -Bu | S | OMe; |
| and 1003 | | <i>i</i> -Pr | O | --- |


66. A pharmaceutical composition comprising an anti-hepatitis C virally effective amount of a compound of formula I according to claim 1, or a therapeutically acceptable salt or ester thereof, in admixture with a pharmaceutically acceptable

carrier medium or auxiliary agent.

67. A method of treating a hepatitis C viral infection in a mammal comprising administering to the mammal an anti-hepatitis C virally effective amount of the compound of formula I according to claim 1, or a therapeutically acceptable salt or ester thereof.
68. A method of treating a hepatitis C viral infection in a mammal comprising administering to the mammal an anti-hepatitis C virally effective amount of the composition according to claim 66.
69. A method of inhibiting the replication of hepatitis C virus comprising exposing the virus to a hepatitis C viral NS3 protease inhibiting amount of the compound of formula I according to claim 1, or a therapeutically acceptable salt or ester thereof.
70. A method of treating a hepatitis C viral infection in a mammal comprising administering thereto an anti-hepatitis C virally effective amount of a combination of the compound of formula I according to claim 1, or a therapeutically acceptable salt or ester thereof with another anti-HCV agent.
71. A method according to claim 70, wherein said other anti-HCV agent is selected from the group consisting of: α - or β -interferon, ribavirin and amantadine.
72. A method according to claim 70, wherein said other anti-HCV agent comprises an inhibitor of other targets in the HCV life cycle, selected from: helicase, polymerase, metalloprotease or IRES.
73. A process for the preparation of a peptide analog of formula (I) according to claim 1 wherein P1 is a substituted aminocyclopropyl carboxylic acid residue, comprising the step of:

coupling a peptide selected from the group consisting of: APG-P3-P2; or APG-P2; with a P1 intermediate of formula:






wherein R^1 is C_{1-6} alkyl, cycloalkyl or C_{2-6} alkenyl, all optionally substituted with halogen, CPG is a carboxyl protecting group and APG is an amino protecting group and P3 and P2 are as defined above.

74. A process for the preparation of: a peptide analog of formula (I) according to claim 1, this process comprising the step of:


coupling a suitably protected amino acid, peptide or peptide fragment with a P1 intermediate of formula:



wherein R^1 is C_{1-6} alkyl, cycloalkyl or C_{2-6} alkenyl, all optionally substituted with halogen, and CPG is a carboxyl protecting group.

75. A process for the preparation of: a peptide analog of formula (I) according to claim 1, this process comprising the step of:

coupling a suitably protected amino acid, peptide or peptide fragment with a P1 intermediate of formula:



wherein CPG is a carboxyl protecting group.

76. A process according to claim 73, 74 or 75 wherein said carboxyl protecting group (CPG) is selected from the group consisting of:

alkyl esters, aralkyl esters, and esters being cleavable by mild base treatment or mild reductive means.

77. Method of preparing a composition for treating a hepatitis C viral infection in a mammal comprising combining an anti-hepatitis C virally effective amount of the compound of formula I according to claim 1, or a therapeutically acceptable salt or ester thereof, with a pharmaceutically acceptable carrier medium or auxiliary agent.

78. Method of preparing a composition for inhibiting the replication of hepatitis C virus comprising combining a hepatitis C viral NS3 protease inhibiting amount of the compound of formula I according to claim 1, or a therapeutically acceptable salt or ester thereof, with a pharmaceutically acceptable carrier medium or auxiliary agent.

79. Method of preparing a composition for treating a hepatitis C viral infection in a mammal comprising combining an anti-hepatitis C virally effective amount of a combination of the compound of formula I according to claim 1, or a therapeutically acceptable salt or ester thereof, and an interferon with a pharmaceutically acceptable carrier medium or auxiliary agent. ✓

